HEALTH● LOW5d ago · Oct 29, 2026, 1:37 PM
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
nynewsly · united states of america · western europe
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease1 The combination vaccine candidate evaluated in this trial pairs Sanofi’s leading high-dose flu vaccine with Novavax’s differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, […]
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapunited states of america and nearby eventsMore from united states of americaLatest stories and threat level
More in Health
HEALTH46m agoCan you get pet insurance after your pet gets sick?CBS NewsHEALTH1h agoRoberto Espinoza, expert in elder care: "In many cases, nursing homes still retain the aesthetics of a hospital. And that's not what people want"ClarínHEALTH2h agoFootball: Spanish player dies on after cardiac arrest on the pitchDW News [en]HEALTH2h agoNew York reports first measles-linked death in over 30 yearsSeeking Alpha Tech